These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8979141)

  • 21. Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines.
    Gurbuz AT; Elliott WG; Zia AA
    Eur J Cardiothorac Surg; 2005 Jan; 27(1):138-49. PubMed ID: 15621486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
    Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
    [No Abstract]   [Full Text] [Related]  

  • 23. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study.
    Turpie AG; Gent M; Côte R; Levine MN; Ginsberg JS; Powers PJ; Leclerc J; Geerts W; Jay R; Neemeh J
    Ann Intern Med; 1992 Sep; 117(5):353-7. PubMed ID: 1503326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current trends in the development of anticoagulant and antithrombotic drugs.
    Fareed J; Hoppensteadt D; Walenga JM; Bick RL
    Med Clin North Am; 1994 May; 78(3):713-31. PubMed ID: 8170266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status on new anticoagulant and antithrombotic drugs and devices.
    Walenga JM; Fareed J
    Curr Opin Pulm Med; 1997 Jul; 3(4):291-302. PubMed ID: 9262116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
    Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
    Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
    Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
    Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
    [No Abstract]   [Full Text] [Related]  

  • 29. Prophylaxis of venous thromboembolism in stroke patients.
    Turpie AG
    Semin Thromb Hemost; 1997; 23(2):155-7. PubMed ID: 9200340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
    Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
    Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anticoagulants in clinical practice].
    Boneu B
    Rev Prat; 1999 Oct; 49(15):1641-7. PubMed ID: 10581994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Successful lysis therapy of inferior vena cava and iliofemoral venous thrombosis in heparin-induced thrombocytopenia type II].
    Fischer KG
    Dtsch Med Wochenschr; 1999 Jan; 124(1-2):32-3. PubMed ID: 9951458
    [No Abstract]   [Full Text] [Related]  

  • 33. [Current status of anticoagulants].
    Oger E; Mottier D
    Presse Med; 2000 May 27-Jun 3; 29(19):1079-82. PubMed ID: 10874921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A; Dawes J
    Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of venous thromboembolism: optimization by clinical trials.
    Turpie AG
    Haemostasis; 1996 Oct; 26 Suppl 4():220-6. PubMed ID: 8979127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of experimental venous thrombosis in rabbits with different low molecular weight heparins, dermatan sulphate and hirudin.
    Matthiasson SE; Lindblad B; Bergqvist D
    Haemostasis; 1995; 25(3):124-32. PubMed ID: 7607580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Low molecular weight heparins].
    Agnelli G; Cosmi B
    Medicina (Firenze); 1990; 10(1):9-15. PubMed ID: 2166209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
    von Segesser LK; Mueller X; Marty B; Horisberger J; Corno A
    Perfusion; 2001 Sep; 16(5):411-6. PubMed ID: 11565896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of deep vein thrombosis following total hip replacement surgery by Orgaran. Summary.
    ten Cate JW
    Haemostasis; 1992; 22(2):109-11. PubMed ID: 1379964
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.